The Global Health Body Issues Warning Over Critical Scarcity of Obesity Injections
Fewer than a tenth of patients that would benefit from weight-loss injections including Wegovy can access them, warns the WHO as it releases its inaugural guidance on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide now living with obesity, it is urging more widespread and fairer availability to GLP-1 medication.
Per projections, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"Our new guidance recognises that excess weight is a chronic disease that can be treated with holistic and lifelong support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are significant hurdles to widespread availability to the treatments that can help people shift substantial weight, explains the organization.
GLP-1 Therapy Shortage
Even under the current most favorable scenario, the production of GLP-1 therapies might only reach about 100 million people – less than 10% of those who need them, per the health organization.
The recommendation urges countries and companies to widen access, through approaches including licensing agreements.
The intellectual property rights on semaglutide – the primary ingredient of the drug Wegovy – is due to expire in several countries in 2026.
How Weight-Loss Jabs Operate
The injections replicate a body's own hormone to reduce digestion speed, reduce hunger and increase feelings of fullness so users reduce food intake.
Patients typically see weight reduction in the initial weeks of commencing the regular doses.
Evidence indicates users may regain a significant portion after a year of discontinuing the medication, as their normal hunger resume.
To be overweight or obese elevates your likelihood for experiencing health problems, such as diabetes, heart disease, brain attack, and some cancers.
Obesity concerns individuals in all nations and was responsible for 3.7 million deaths worldwide in 2024, as per the health agency.